Details

Autor(en) / Beteiligte

• Cheng, Xu
• Liu, Ye-Mao
• Li, Haomiao
• Zhang, Xin
• Lei, Fang
• Qin, Juan-Juan
• Chen, Ze
• Deng, Ke-Qiong
• Lin, Lijin
• Chen, Ming-Ming
• Song, Xiaohui
• Xia, Meng
• Huang, Xuewei
• Liu, Weifang
• Cai, Jingjing
• Zhang, Xiao-Jing
• Zhou, Feng
• Zhang, Peng
• Wang, Yibin
• Ma, Xinliang
• Xu, Qingbo
• Yang, Juan
• Ye, Ping
• Mao, Weiming
• Huang, Xiaodong
• Xia, Jiahong
• Zhang, Bing-Hong
• Guo, Jiao
• Zhu, Lihua
• Lu, Zhibing
• Yuan, Yufeng
• Wei, Xiang
• She, Zhi-Gang
• Ji, Yan-Xiao
• Li, Hongliang

Titel

Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes

Ist Teil von

• Cell metabolism, 2020-10, Vol.32 (4), p.537-547.e3

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Quelle

ScienceDirect

Beschreibungen/Notizen

• The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and pre-existing type 2 diabetes (T2D). Metformin is the most commonly prescribed first-line medication for T2D, but its impact on the outcomes of individuals with COVID-19 and T2D remains to be clarified. Our current retrospective study in a cohort of 1,213 hospitalized individuals with COVID-19 and pre-existing T2D indicated that metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality. Furthermore, metformin use was significantly associated with reduced heart failure and inflammation. Our findings provide clinical evidence in support of continuing metformin treatment in individuals with COVID-19 and pre-existing T2D, but acidosis and kidney function should be carefully monitored in individuals with severe COVID-19. [Display omitted] •A retrospective study of 1,213 patients on metformin with COVID-19 was performed•Metformin was associated with increased incidence of acidosis in such patients•Metformin was not associated with increased 28-day all-cause mortality in the patients•Metformin was significantly associated with reduced heart failure and inflammation In a cohort of 1,213 hospitalized patients with COVID-19 and pre-existing type 2 diabetes, Cheng et al. show that metformin use is significantly associated with higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day all-cause mortality. They also found that metformin use is significantly associated with reduced heart failure and inflammation.